Orig3n Inc, a Boston-based biotech company involved in genetics and regenerative medicine research, has acquired Interleukin Genetics CLIA laboratory and its remaining assets, it was reported yesterday.

The acquisition is intended to allow Interleukin Genetics' technology to become a core component of Orig3n's DNA test business.

The automated genotyping lab is completely-licensed for testing in all 50 US states and is capable of processing over one million samples per annum. In addition to the company's technology and its HIPAA and HITECH compliance, Interleukin Genetics also provides Orig3n with its ILUSTRA Inflammation Management Program and its Inherent Health genetic tests for nutritional needs, weight management, heart health, and bone health.